Alexion nears $25M settlement with SEC in FCPA probe
By 
Jaclyn Jaeger2020-05-07T14:19:00
Alexion Pharmaceuticals said in a regulatory filing that it is nearing a $25 million settlement with the Securities and Exchange Commission concerning an investigation into the company’s compliance with the Foreign Corrupt Practices Act spanning various countries.
Related articles
-
ArticleAlexion Pharmaceuticals to pay $21M to resolve FCPA case
Alexion Pharmaceuticals will pay $21 million to resolve SEC charges that it violated the books and records and internal accounting controls provisions of the FCPA concerning bribes made by subsidiaries to foreign government officials.
-
Blog
Alexion Pharmaceuticals Discloses FCPA Probe
Alexion Pharmaceuticals said this week in a securities filing that it is being investigated by the Department of Justice concerning potential violations of the Foreign Corrupt Practices Act. As previously disclosed, Alexion received a subpoena in May in connection with an investigation by the SEC’s Enforcement Division “requesting information related ...
-
Opinion5 best practices of running an effective internal investigations program
In today’s complex and rapidly evolving regulatory compliance environment, organizations should have a thorough and effective internal investigations program in place to address any allegations of misconduct.
More from Regulatory Enforcement
-
News BriefFTC complaint accuses LA Fitness parent companies of blocking easy membership exits
The Federal Trade Commission filed a complaint against LA Fitness’ parent companies, citing difficulties canceling memberships, a month after a court blocked the agency’s click-to-cancel rule.
-
ArticleJudge orders CVS to pay nearly $290M for Medicare false claims
CVS’s Caremark division knowingly overcharged Medicare for prescription drugs and must pay nearly $290 million, a Pennsylvania federal judge has ordered.
-
News BriefSEC charges duo in $275 million water vending machine Ponzi scheme
The owner of a water machine vending company and a portfolio manager were allegedly behind a Ponzi-like scheme that raised more than $275 million, according to the U.S. Securities and Exchange Commission.